Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Cancer Treatment Reviews
|
July 1, 1994
Hormone therapy in advanced breast carcinoma: present and future trends
E Bajetta, N Zilembo, A Di Leo, et al.
Oncology
|
November 1, 1995
Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer
C Noberasco, E Bajetta, N Zilembo, et al.
Critical Reviews in Oncology/Hematology
|
December 31, 2013
Targeted therapy-induced diarrhea: A review of the literature
M A Pessi, N Zilembo, E R Haspinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2000
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors
E Bajetta, N Zilembo, E Bichisao, et al.
Cancer
|
January 15, 1996
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group
M di Bartolomeo, E Bajetta, R Buzzoni, et al.
Tumori
|
December 31, 1994
Formestane as treatment of advanced breast cancer in elderly women
N Zilembo, R Buzzoni, L Celio, et al.
Tumori
|
February 28, 1994
Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer
E Bajetta, L Celio, N Zilembo, et al.
Cancer
|
August 22, 2000
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial
E Bajetta, S Chiara Stani, D De Candis, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
January 1, 1997
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane
A Martinetti, E Bajetta, E Seregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
G Procopio, E Verzoni, S Bracarda, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Cancer Treatment Reviews
|
July 1, 1994
Hormone therapy in advanced breast carcinoma: present and future trends
E Bajetta, N Zilembo, A Di Leo, et al.
Oncology
|
November 1, 1995
Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer
C Noberasco, E Bajetta, N Zilembo, et al.
Critical Reviews in Oncology/Hematology
|
December 31, 2013
Targeted therapy-induced diarrhea: A review of the literature
M A Pessi, N Zilembo, E R Haspinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2000
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors
E Bajetta, N Zilembo, E Bichisao, et al.
Cancer
|
January 15, 1996
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group
M di Bartolomeo, E Bajetta, R Buzzoni, et al.
Tumori
|
December 31, 1994
Formestane as treatment of advanced breast cancer in elderly women
N Zilembo, R Buzzoni, L Celio, et al.
Tumori
|
February 28, 1994
Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer
E Bajetta, L Celio, N Zilembo, et al.
Cancer
|
August 22, 2000
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial
E Bajetta, S Chiara Stani, D De Candis, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
January 1, 1997
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane
A Martinetti, E Bajetta, E Seregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
G Procopio, E Verzoni, S Bracarda, et al.
Page
of 6